Litcius/Paper detail

Survival outcomes in locally advanced dMMR rectal cancer: surgery plus adjunctive treatment vs. surgery alone

Kemin Ni, Yixiang Zhan, Zhaoce Liu, Zhen Yuan, Shuyuan Wang, Xuanzhu Zhao, Hangyu Ping, Yaohong Liu, Wanting Wang, Suying Yan, Ran Xin, Qiurong Han, Qinghuai Zhang, Guoxun Li, Xipeng Zhang, Guihua Wang, Zili Zhang, H. Ma, Chunze Zhang

2023BMC Cancer11 citationsDOIOpen Access PDF

Abstract

BACKGROUND: Recent studies have shown that deficient mismatch repair (dMMR) rectal cancer may be related to treatment resistance, resulting in a worse prognosis than proficient MMR (pMMR) rectal cancer. The purpose of this study was to explore whether surgery plus other treatments (radiotherapy and chemotherapy) can bring more benefits to these patients than surgery alone. METHODS: A retrospective study of 168 patients with rectal adenocarcinoma who underwent total mesorectal excision was conducted using immunohistochemical methods to determine MMR status and a propensity score matching model to minimize potential confounding factors between subgroups of patients with different treatment regimens. Kaplan-Meier analysis, log-rank tests, and Cox regression models were used to assess overall survival (OS) and disease-free survival (DFS) in patient subgroups. RESULTS: Only 6.9% (n = 168) of patients in the total cohort had dMMR rectal adenocarcinoma, and the most common cause of dMMR was a PMS2 deletion (103, 61.3%). The median DFS of the surgery alone group was 45.7 months (IQR, 40.9 to 77.8), and the median DFS of the surgery plus other treatment group was 43.9 months (IQR, 14.2 to 80.1). The surgery alone group was superior to the surgery plus other treatment group (HR, 0.16; 95% CI, 0.07 to 0.38; p = 0.005). There was no significant difference in OS (45.8 (IQR, 41.0 to 79.8) vs. 45.9 (IQR, 38.5 to 80.3)) between the two groups (HR, 0.57; 95% CI, 0.23 to 1.40; p = 0.263). CONCLUSIONS: For patients with locally advanced dMMR rectal adenocarcinoma, compared with surgery alone, surgery plus other treatment options (radiotherapy and chemotherapy) do not grant long-term survival benefits but rather shorten DFS.

Topics & Concepts

MedicineTotal mesorectal excisionColorectal cancerPropensity score matchingInternal medicineSurgical oncologyProportional hazards modelRetrospective cohort studyAdenocarcinomaOncologySurgeryCancerGenetic factors in colorectal cancerColorectal Cancer Surgical TreatmentsColorectal Cancer Screening and Detection